PT - JOURNAL ARTICLE AU - Eva Bednarski AU - Perla M Del Rio Estrada AU - Justin DaSilva AU - Celia Boukadida AU - Fengwen Zhang AU - Yara A Luna-Villalobos AU - Ximena Rodríguez-Rangel AU - Elvira Pitén-Isidro AU - Edgar Luna-García AU - Dafne Díaz Rivera AU - Dulce M López-Sánchez AU - Daniela Tapia-Trejo AU - Maribel Soto-Nava AU - Myriam Astorga-Castañeda AU - José O Martínez-Moreno AU - Guadalupe S Urbina-Granados AU - José A Jiménez-Jacinto AU - Francisco J Serna Alvarado AU - Yerania E Enriquez-López AU - Oliva López-Arellano AU - Gustavo Reyes-Teran AU - Paul D. Bieniasz AU - Santiago Avila-Rios AU - Theodora Hatziioannou TI - Antibody and memory B-cell immunity in a heterogeneously SARS-CoV-2 infected and vaccinated population AID - 10.1101/2022.02.07.22270626 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.07.22270626 4099 - http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270626.short 4100 - http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270626.full AB - Global population immunity to SARS-CoV-2 is accumulating through heterogenous combinations of infection and vaccination. Vaccine distribution in low- and middle-income countries has been variable and reliant on diverse vaccine platforms. We studied B-cell immunity in Mexico, a middle-income country where five different vaccines have been deployed to populations with high SARS-CoV-2 incidence. Levels of antibodies that bound a stabilized prefusion spike trimer, neutralizing antibody titers and memory B-cell expansion correlated with each other across vaccine platforms. Nevertheless, the vaccines elicited variable levels of B-cell immunity, and the majority of recipients had undetectable neutralizing activity against the recently emergent omicron variant. SARS-CoV-2 infection, experienced prior to or after vaccination potentiated B-cell immune responses and enabled the generation of neutralizing activity against omicron and SARS-CoV for all vaccines in nearly all individuals. These findings suggest that broad population immunity to SARS-CoV-2 will eventually be achieved, but by heterogenous pathsCompeting Interest StatementPDB has received compensation from Pfizer for consultation in the area of SARS-CoV-2 vaccinesFunding StatementThis work was supported by the Mexican Government (Programa Presupuestal P016; Anexo 13 del Decreto del Presupuesto de Egresos de la Federacion) by NIH grants R37AI64003 and R01AI501111 (PDB); R01AI78788 (TH) and P01AI165075 (PDB and TH)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocols set forth and approved by the Comite de Etica en Investigacion and the Comite de Investigacion (Research Ethics Committee and the Research Committee) from INER Institutional Review Board (study no. B01-21)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript